Shares of Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF – Get Free Report) shot up 3.7% on Friday . The company traded as high as $25.02 and last traded at $25.02. 3,835 shares changed hands during trading, an increase of 1,146% from the average session volume of 308 shares. The stock had previously closed at $24.12.
Analyst Ratings Changes
Separately, Royal Bank of Canada upgraded Hikma Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Tuesday, December 10th.
Read Our Latest Research Report on HKMPF
Hikma Pharmaceuticals Stock Performance
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Featured Articles
- Five stocks we like better than Hikma Pharmaceuticals
- Retail Stocks Investing, Explained
- Cold Front, Hot Stocks: Diesel Prices Propel Energy Leaders
- What is the Dow Jones Industrial Average (DJIA)?
- Sustainable and Successful: 3 Climate ETFs Beating the Market
- What is the S&P 500 and How It is Distinct from Other Indexes
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
